10 / 10
Page 49
Notes:
Journal of Biotechnology & Biomaterials | ISSN: 2155-952X | Volume: 8
July 23-24, 2018 | Vancouver, Canada
Annual Biotechnology Congress
Targeting therapy of hepatocarcinoma by a peptide directed doxorubicin/miRNA liposome
Yingchun Hou
Shaanxi Normal University, China
H
epatocellular carcinoma (HCC) is a severe malignant disease to threaten human life safety, and current chemical
therapeutic methods are usually developed with low efficacy and high side effects because they have no enough specific
targeting to cancer cells and cannot inhibit the multiple drug resistance (MDR) of chemical therapeutics. HCSP4, a 12aa
peptide was screened out in our lab using the bio-panning method from a phage displayed peptide library, and it binds to
HCC cells with high specificity and sensitivity. In our study, to develop a HCC targeting chemical therapeutic delivery system
with high HCC therapeutic efficacy, low side effects and satisfactory resistance for MDR, HCSP4 and miR101 were used to
construct the HCC targeting DOX (doxorubicin) delivery liposome system, HCSP4-Lipo-miR101-DOX. The results in vitro
showed that HCSP4-Lipo-miR101-DOX presented the much enhanced cytotoxicity to HepG2 cells and HepG2/ADR cells
(DOX resistant HCC cells). To explore the mechanism by that HCSP4-Lipo-miR101-DOX presents the reversal of MDR of
DOX, the expression of the genes were of the potential to be the targets of miR101 was detected with western blot. The result
indicated that the expression of some genes associated with membrane transportation and cancer growth was significantly
inhibited, such as ABCC5, COX-2, P-gp, VEGF, STX1A, and EZH2. The results above suggested that the HCSP4 conjugated
DOX delivery system, HCSP4-Lipo -miR101-DOX is of the great promising potential to be developed as an important efficient
drug system for the therapy of HCC with low recurrence, its mechanism against MDR is discussed in the study. This approach
is also an important strategy can be referenced for other cancer therapeutics study.
Biography
Yingchun Hou has completed his MD and PhD degrees in 1997 at The Fourth Military Medical University, China. He has his experience as Postdoctoral Scholar,
Postdoctoral Research Associate and Senior Scientist in USA NIH and other institutions from 1998 to 2006. From January 2006 to date, he holds the position of
Professor and PI in Shaanxi Normal University, China. His researches focus on the molecular and cellular biology of cancer, published papers more than 100, and
got 10 of Chinese patents approved. He concluded and created the theory of spatiotemporal cell biology and its core frame, triple W and signal basin in the world
firstly. He is the Associate Chairman for the Shaanxi Society for Genome and Health, the Member of the American Society for Biochemistry and Molecular Biology,
and the Member of American Society for Microbiology. His current research projects include the functions of tumor associated genes and signal regulation and the
target to cancer cells and the targeting therapy for cancers.
ychhou@snnu.edu.cnYingchun Hou, J Biotechnol Biomater 2018, Volume: 8
DOI: 10.4172/2155-952X-C3-094